# Gecombineerde MASLD en sarcopenie bij obesitas verhoogt risico op CVD, nierfalen en overlijden — UK Biobank

*geplaatst 2026-11-08 · Nierziekte · MedComm · doi 10.1002/mco2.71111 · https://hartvaat.nl/2026/11/01/gecombineerde-masld-en-sarcopenie-bij-obesitas-verhoogt-risico-op-cvd-nierfalen-/*

In een prospectieve UK Biobank-cohort van 438.748 deelnemers werd de gezamenlijke invloed van MASLD en sarcopenie op cardiometabole en renale uitkomsten onderzocht. De gecombineerde aanwezigheid van MASLD, lage spierkracht en obesitas werd geassocieerd met een sterk verhoogd risico op cirrose (gecorrigeerd HR 8,48), CVD, nierfalen en overlijden, met een stapsgewijze risicotoename per sarcopenie- en obesitasklasse. Deze bevindingen benadrukken de noodzaak om sarcopenie en spierfunctie systematisch in kaart te brengen bij patiënten met MASLD en obesitas voor betere risicostratificatie en preventie van hart- en vaat- en niercomplicaties.

## English: Associations of Coexisting Metabolic Dysfunction-Associated Steatotic Liver Disease and Sarcopenia-Related Abnormalities With Adverse Clinical Outcomes Across Obesity States.

In a prospective UK Biobank cohort of 438,748 participants, researchers evaluated the joint impact of metabolic dysfunction-associated steatotic liver disease (MASLD) and sarcopenia-related abnormalities on cardiovascular, renal, and mortality outcomes. The coexistence of MASLD, low muscle strength, and obesity was associated with a stepwise increase in adverse events, with the highest adjusted hazard ratio for cirrhosis reaching 8.48, alongside significantly elevated risks for CVD, chronic kidney disease, and all-cause mortality. These findings highlight the clinical value of integrating sarcopenia assessment into routine MASLD management to refine cardiovascular and renal risk stratification.

## Abstract (original, from the publication)

Metabolic dysfunction-associated steatotic liver disease (MASLD) is associated with adverse liver and non-liver outcomes, but the impact of coexisting sarcopenia-related abnormalities (e.g., low muscle strength [MS], muscle mass, and physical performance) remains unclear. In a prospective UK Biobank cohort (n = 438,748), we evaluated their joint associations with incidence and risks of all-cause mortality, cirrhosis, hepatocellular carcinoma (HCC), cardiovascular disease (CVD), chronic kidney disease (CKD), non-liver cancers, and obesity-related cancers across MASLD and sarcopenia-related abnormality status. Over a median follow-up of 13.8 years, 401 HCC, 1714 cirrhosis, 39,534 CVD, 19,637 CKD, 38,240 non-liver cancers, 12,536 obesity-related cancers, and 34,801 deaths occurred. A stepwise increase in both incidence and adjusted risk of liver and non-liver outcomes was observed across MASLD and sarcopenia strata. Within the coexistence group, the obesity (vs. non-obesity) subgroup generally had higher risks. For example, for cirrhosis, adjusted hazard ratios increased from 3.93 to 7.36 then 8.48 with MASLD alone, coexisting MASLD with low MS overall and coexisting MASLD, low MS and obesity, respectively. Similar findings were observed in external validation analyses using the 2011-2018 US National Health and Nutrition Examination Survey cohort. Together, these observations inform risk stratification strategy and management of MASLD to include sarcopenia assessment.

Auteurs: Hong Fan, Xianhua Mao, Taotao Yan, Scott Barnett, Jing Zhang, Ramsey Cheung, Xuehong Zhang, Mindie H Nguyen

---
Bron: MedComm, https://doi.org/10.1002/mco2.71111. Bijgewerkt 2026-11-01T02:40:28Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.